We are pleased to announce the Antibodies Editor's Choice Articles published in 2020 and 2021. Editor’s Choice Articles are selected based on suggestions from the academic editors of Antibodies (ISSN: 2073-4468) from around the world. Editors select a small number of articles recently published in the journal that they consider to be of particular interest to readers or important in their respective fields of research. We are delighted to present the Editor's Choice Articles from 2020 and 2021, a curated list of high-quality articles from Antibodies. The full list of Editor’s Choice Articles can be found at the following link: https://www.mdpi.com/journal/antibodies/editors_choice. 

“Monoclonal Antibodies in Cancer Therapy”
by David Zahavi and Louis Weiner
Antibodies 2020, 9(3), 34; https://doi.org/10.3390/antib9030034
Available online: https://www.mdpi.com/2073-4468/9/3/34
Cited by 147 | Viewed by 17551 

“Antibody Conjugates-Recent Advances and Future Innovations”
by Donmienne Leung, Jacqueline M. Wurst, Tao Liu, Ruben M. Martinez, Amita Datta-Mannan and Yiqing Feng
Antibodies 2020, 9(1), 2; https://doi.org/10.3390/antib9010002
Available online: https://www.mdpi.com/2073-4468/9/1/2
Cited by 51 | Viewed by 12315 

“From Anti-SARS-CoV-2 Immune Responses to COVID-19 via Molecular Mimicry”
by Darja Kanduc
Antibodies 2020, 9(3), 33; https://doi.org/10.3390/antib9030033
Available online: https://www.mdpi.com/2073-4468/9/3/33
Cited by 48 | Viewed by 12455 

“Structure, Function, and Therapeutic Use of IgM Antibodies”
by Bruce A. Keyt, Ramesh Baliga, Angus M. Sinclair, Stephen F. Carroll and Marvin S. Peterson
Antibodies 2020, 9(4), 53; https://doi.org/10.3390/antib9040053
Available online: https://www.mdpi.com/2073-4468/9/4/53
Cited by 45 | Viewed by 10761 

“Fc-Engineering for Modulated Effector Functions—Improving Antibodies for Cancer Treatment”
by Rena Liu, Robert J. Oldham, Emma Teal, Stephen A. Beers and Mark S. Cragg
Antibodies 2020, 9(4), 64; https://doi.org/10.3390/antib9040064
Available online: https://www.mdpi.com/2073-4468/9/4/64
Cited by 42 | Viewed by 11394 

“Principles of N-Linked Glycosylation Variations of IgG-Based Therapeutics: Pharmacokinetic and Functional Considerations”
by Souad Boune, Peisheng Hu, Alan L. Epstein and Leslie A. Khawli
Antibodies 2020, 9(2), 22; https://doi.org/10.3390/antib9020022
Available online: https://www.mdpi.com/2073-4468/9/2/22
Cited by 25 | Viewed by 9663 

“Complement System: Promoter or Suppressor of Cancer Progression?”
by Margot Revel, Marie V. Daugan, Catherine Sautés-Fridman, Wolf H. Fridman and Lubka T. Roumenina
Antibodies 2020, 9(4), 57; https://doi.org/10.3390/antib9040057
Available online: https://www.mdpi.com/2073-4468/9/4/57
Cited by 21 | Viewed by 4840 

“A Review of Deep Learning Methods for Antibodies”
by Jordan Graves, Jacob Byerly, Eduardo Priego, Naren Makkapati, S. Vince Parish, Brenda Medellin and Monica Berrondo
Antibodies 2020, 9(2), 12; https://doi.org/10.3390/antib9020012
Available online: https://www.mdpi.com/2073-4468/9/2/12
Cited by 21 | Viewed by 11852 

“Human Natural Antibodies to Mammalian Carbohydrate Antigens as Unsung Heroes Protecting against Past, Present, and Future Viral Infections”
by Uri Galili
Antibodies 2020, 9(2), 25; https://doi.org/10.3390/antib9020025
Available online: https://www.mdpi.com/2073-4468/9/2/25
Cited by 20 | Viewed by 4329 

“The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs”
by Josée Golay and Ronald P. Taylor
Antibodies 2020, 9(4), 58; https://doi.org/10.3390/antib9040058
Available online: https://www.mdpi.com/2073-4468/9/4/58
Cited by 19 | Viewed by 4898 

“A Purification Strategy Utilizing Hydrophobic Interaction Chromatography to Obtain Homogeneous Species from a Site-Specific Antibody Drug Conjugate Produced by AJICAP™ First Generation”
by Yutaka Matsuda, Monica Leung, Tatsuya Okuzumi and Brian Mendelsohn
Antibodies 2020, 9(2), 16; https://doi.org/10.3390/antib9020016
Available online: https://www.mdpi.com/2073-4468/9/2/16
Cited by 17 | Viewed by 5788 

“Antinuclear Autoantibodies in Health: Autoimmunity Is Not a Synonym of Autoimmune Disease”
by Irina A. Pashnina, Irina M. Krivolapova, Tamara V. Fedotkina, Varvara A. Ryabkova, Margarita V. Chereshneva, Leonid P. Churilov and Valeriy A. Chereshnev
Antibodies 2021, 10(1), 9; https://doi.org/10.3390/antib10010009
Available online: https://www.mdpi.com/2073-4468/10/1/9
Cited by 17 | Viewed by 6924 

“Structural Features and PF4 Functions that Occur in Heparin-Induced Thrombocytopenia (HIT) Complicated by COVID-19”
by Zheng Cai, Mark I. Greene, Zhiqiang Zhu and Hongtao Zhang
Antibodies 2020, 9(4), 52; https://doi.org/10.3390/antib9040052
Available online: https://www.mdpi.com/2073-4468/9/4/52
Cited by 17 | Viewed by 4795 

“Fc Engineering Strategies to Advance IgA Antibodies as Therapeutic Agents”
by Geert van Tetering, Geert, Mitchell Evers, Chilam Chan, Marjolein Stip and Jeanette Leusen
Antibodies 2020, 9(4), 70; https://doi.org/10.3390/antib9040070
Available online: https://www.mdpi.com/2073-4468/9/4/70
Cited by 14 | Viewed by 4550 

“IgE Antibodies against Cancer: Efficacy and Safety”
by Jitesh Chauhan, Alex J. McCraw, Mano Nakamura, Gabriel Osborn, Heng Sheng Sow, Vivienne F. Cox, Chara Stavraka, Debra H. Josephs, James F. Spicer, Sophia N. Karagiannis et al.
Antibodies 2020, 9(4), 55; https://doi.org/10.3390/antib9040055
Available online: https://www.mdpi.com/2073-4468/9/4/55
Cited by 13 | Viewed by 5176 

“Beyond the Lactate Paradox: How Lactate and Acidity Impact T Cell Therapies against Cancer”
by Violet Y. Tu, Asma Ayari and Roddy S. O’Connor
Antibodies 2021, 10(3), 25; https://doi.org/10.3390/antib10030025
Available online: https://www.mdpi.com/2073-4468/10/3/25
Cited by 12 | Viewed by 4200 

“Utilizing Immunocytokines for Cancer Therapy”
by Erin Runbeck, Silvia Crescioli, Sophia N. Karagiannis and Sophie Papa
Antibodies 2021, 10(1), 10; https://doi.org/10.3390/antib10010010
Available online: https://www.mdpi.com/2073-4468/10/1/10
Cited by 11 | Viewed by 4707 

“Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies”
by Josée Golay and Alain E. Andrea
Antibodies 2020, 9(2), 17; https://doi.org/10.3390/antib9020017
Available online: https://www.mdpi.com/2073-4468/9/2/17
Cited by 10 | Viewed by 5100 

“Intravenous Immune Globulin Uses in the Fetus and Neonate: A Review”
by Mahdi Alsaleem
Antibodies 2020, 9(4), 60; https://doi.org/10.3390/antib9040060
Available online: https://www.mdpi.com/2073-4468/9/4/60
Cited by 10 | Viewed by 5880 

“IgE Autoreactivity in Atopic Dermatitis: Paving the Road for Autoimmune Diseases?”
by Christophe Pellefigues
Antibodies 2020, 9(3), 47; https://doi.org/10.3390/antib9030047
Available online: https://www.mdpi.com/2073-4468/9/3/47
Cited by 10 | Viewed by 3813 

“Antibody Screening by Microarray Technology—Direct Identification of Selective High-Affinity Clones”
by Martin Paul and Michael G. Weller
Antibodies 2020, 9(1), 1; https://doi.org/10.3390/antib9010001
Available online: https://www.mdpi.com/2073-4468/9/1/1
Cited by 9 | Viewed by 5988 

“Discovery Strategies to Maximize the Clinical Potential of T-Cell Engaging Antibodies for the Treatment of Solid Tumors”
by Vladimir Voynov, Paul J. Adam, Andrew E. Nixon and Justin M. Scheer
Antibodies 2020, 9(4), 65; https://doi.org/10.3390/antib9040065
Available online: https://www.mdpi.com/2073-4468/9/4/65
Cited by 9 | Viewed by 4841 

“Recent Advances in the Molecular Design and Applications of Multispecific Biotherapeutics”
by Xiaotian Zhong and Aaron M. D’Antona
Antibodies 2021, 10(2), 13; https://doi.org/10.3390/antib10020013
Available online: https://www.mdpi.com/2073-4468/10/2/13
Cited by 9 | Viewed by 5743 

“The Course of SARS-COV2 Infection Was Not Severe in a Crohn’s Patient Who Administered Maintenance Anti-TNF Therapy Overlapping the Early Pre-Symptomatic Period of Infection”
by Francis Okeke, Anjali Mone and Arun Swaminath
Antibodies 2020, 9(3), 42; https://doi.org/10.3390/antib9030042
Available online: https://www.mdpi.com/2073-4468/9/3/42
Cited by 8 | Viewed by 4231 

“Introduction to Antibody-Drug Conjugates”
by Mark C. Pettinato
Antibodies 2021, 10(4), 42; https://doi.org/10.3390/antib10040042
https://www.mdpi.com/2073-4468/10/4/42
Cited by 8 | Viewed by 3767 

“An Immunoregulatory Role for Complement Receptors in Murine Models of Breast Cancer”
by Fazrena Nadia Md Akhir, Mohd Hezmee Mohd Noor, Keith Weng Kit Leong, Jamileh A. Nabizadeh, Helga D. Manthey, Stefan E. Sonderegger, Jenny Nga Ting Fung, Crystal E. McGirr, Ian A. Shiels, Paul C. Mills et al.
Antibodies 2021, 10(1), 2; https://doi.org/10.3390/antib10010002
Available online: https://www.mdpi.com/2073-4468/10/1/2
Cited by 7 | Viewed by 3239 

“From Anti-SARS-CoV-2 Immune Response to the Cytokine Storm via Molecular Mimicry”
by Darja Kanduc
Antibodies 2021, 10(4), 36; https://doi.org/10.3390/antib10040036
Available online: https://www.mdpi.com/2073-4468/10/4/36
Cited by 6 | Viewed by 3821 

“Improving Receptor-Mediated Intracellular Access and Accumulation of Antibody Therapeutics—The Tale of HER2”
by Jeffrey V. Leyton
Antibodies 2020, 9(3), 32; https://doi.org/10.3390/antib9030032
https://www.mdpi.com/2073-4468/9/3/32
Cited by 6 | Viewed by 4632 

“HDX-MS for Epitope Characterization of a Therapeutic ANTIBODY Candidate on the Calcium-Binding Protein Annexin-A1”
by Marius Gramlich, Henry C. W. Hays, Scott Crichton, Philipp D. Kaiser, Anne Heine, Nicole Schneiderhan-Marra, Ulrich Rothbauer, Dieter Stoll, Sandra Maier and Anne Zeck
Antibodies 2021, 10(1), 11; https://doi.org/10.3390/antib10010011
Available online: https://www.mdpi.com/2073-4468/10/1/11
Cited by 6 | Viewed by 3507 

“Importance and Considerations of Antibody Engineering in Antibody-Drug Conjugates Development from a Clinical Pharmacologist’s Perspective”
by Andrew T. Lucas, Amber Moody, Allison N. Schorzman and William C. Zamboni
Antibodies 2021, 10(3), 30; https://doi.org/10.3390/antib10030030
Available online: https://www.mdpi.com/2073-4468/10/3/30
Cited by 6 | Viewed by 4572 

“Tinkering under the Hood: Metabolic Optimisation of CAR-T Cell Therapy”
by Yasmin Jenkins, Joanna Zabkiewicz, Oliver Ottmann and Nicholas Jones
Antibodies 2021, 10(2), 17; https://doi.org/10.3390/antib10020017
Available online: https://www.mdpi.com/2073-4468/10/2/17
Cited by 6 | Viewed by 4406 

“Viroinformatics-Based Analysis of SARS-CoV-2 Core Proteins for Potential Therapeutic Targets”
by Lokesh Agrawal, Thanasis Poullikkas, Scott Eisenhower, Carlo Monsanto, Ranjith Kumar Bakku, Min-Hua Chen and Rajkumar Singh Kalra
Antibodies 2021, 10(1), 3; https://doi.org/10.3390/antib10010003
Available online: https://www.mdpi.com/2073-4468/10/1/3
Cited by 5 | Viewed by 5233 

“New Autoantibody Specificities in Systemic Sclerosis and Very Early Systemic Sclerosis”
by Roberto Lande, Raffaella Palazzo, Anna Mennella, Immacolata Pietraforte, Marius Cadar, Katia Stefanantoni, Curdin Conrad, Valeria Riccieri and Loredana Frasca
Antibodies 2021, 10(2), 12; https://doi.org/10.3390/antib10020012
Available online: https://www.mdpi.com/2073-4468/10/2/12
Cited by 4 | Viewed by 3213